For its fourth fiscal quarter (ending December 31), Theravance Biopharma Inc (NASDAQ: TBPH) has reported E.P.S. of $-0.17 compared to $-0.21 a year ago. This result fell short of the consensus estimate of $-0.00 by $-0.17. E.P.S. were $-1.00 for the latest four quarters through December 31 versus $-1.26 for the same period a year ago.
Recent Price Action
Theravance Biopharma Inc (NASDAQ: TBPH) stock closed at $9.23 on 2/26/24 after a large increase of 2.8%. However, unusually low trading volume at 61% of normal accompanied the advance. The stock has risen 6.5% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
TBPH is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Theravance Biopharma has a current Value Trend Rating of F (Lowest Rating). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Theravance Biopharma has a slightly negative Power Rating of 39 and a poor Appreciation Score of 23, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment